The federal Food and Drug Administration October 3 approved a new daily PrEP pill that could offer a safer option for some individuals at risk for HIV, but the indication does not cover everyone who ...

A new HIV prevention option works well for gay and bisexual men and transgender women and should be approved by the Food and Drug Administration for these populations, according to an expert advisory ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial indicating that the ...

In it, the safety and efficacy of a twice-yearly, under-the-skin (subcutaneous) injection of lenacapavir for PrEP was compared with once-daily oral Descovy or Truvada in more than 5,300 cisgender ...

Gilead Sciences, Inc. GILD announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a phase III, double-blind, randomized study evaluating the safety ...

Much has changed in the world of HIV pre-exposure prophylaxis (PrEP) in the four years since COVID-19 shut down the world — from delivery methods to length of time between treatments. In 2024, there ...

Add Yahoo as a preferred source to see more of our stories on Google. a group of fit men in blue and white outfits promote national prep day Today is the first National PrEP Day — a new annual event ...